Catyalyst Pharma (NASDAQ: CPRX) on August 31st received FDA orphan drug designation for its treatment of myasthenia gravis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE